Health Care Firms Gain New Voluntary Disclosure Process
Health care operators can now pursue financial damage caps through a new, centralized DOJ reporting process.
Updated on Oct. 15, 2026 in Healthcare
Live Poll
Do you trust that new government policies will effectively reduce corporate fraud in health care?
The Department of Justice has launched a centralized voluntary self-disclosure process for health care entities to report compliance failures. This initiative seeks to provide companies with capped financial damages while the agency simultaneously upgrades its use of AI-driven analytics to detect fraud.
Why it matters
The DOJ aims to protect taxpayer-funded programs like Medicare by incentivizing corporate self-reporting and remediating misconduct before investigators intervene. By standardizing the disclosure path, the department clarifies how businesses can mitigate liability if they identify internal compliance gaps.
The Department of Justice now prioritizes investigations into fraud schemes that have persisted for 3 years or longer. This centralized process covers health care companies and applies to potential violations including illegal controlled substance distribution and federal Food, Drug, and Cosmetic Act breaches.
The players
Department of Justice
The federal agency responsible for enforcing laws and prosecuting health care fraud within the United States.
Department of Health and Human Services
The federal department that administers taxpayer-funded health programs, including Medicare.
Colin M. McDonald
The Assistant Attorney General who authored the October 1, 2026 memo on whistleblower incentive programs.
The details
Companies can now utilize a single point of contact at the Department of Justice to submit self-disclosures, which allows them to seek caps on potential financial damages from both the DOJ and the Department of Health and Human Services. Concurrently, the agency is deploying data analytics and artificial intelligence to identify irregularities, such as billing for unnecessary services or fabricated patient records, to better detect corporate wrongdoing.
Timeline
October 1, 2026: Assistant Attorney General Colin M. McDonald issued a memo regarding whistleblower incentives.
October 2026: The Department of Justice announced these policy changes at the STAT Summit in Boston.
Market Landscape
This policy marks a strategic shift in how the DOJ manages compliance enforcement and corporate liability for health care firms. It increases the agency's investigative focus on violations of the federal Food, Drug, and Cosmetic Act while formalizing the incentives for proactive reporting.
Compliance officers should review internal audit protocols to identify potential violations that meet the three-year duration threshold for enhanced scrutiny. Entities should consult with qualified legal counsel to determine the benefits of utilizing the new centralized disclosure path versus maintaining existing monitoring procedures.
The takeaway
The DOJ is increasing its reliance on artificial intelligence to audit and detect fraudulent billing patterns across the health care sector. Operators should prioritize rigorous data-integrity reviews to ensure that patient records and billing claims remain accurate and defensible against these automated tools.
Further reading
For more on industry compliance and legal shifts, visit Healthcare.
Source note: This article includes information reported by STAT.
Live Poll
Do you trust that new government policies will effectively reduce corporate fraud in health care?
